Julio Vázquez-Martínez

Dr. Julio Vázquez-Martínez

Escuela Nacional de Ciencias Biológicas, IPN
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2025 in Research Square
Verified
Preprint
Open access
PDF file
MDMarco Davila
Marco Davila
SLSae Bom Lee
Sae Bom Lee
YKYun Pyo Kang
Yun Pyo Kang
JBJustin Boucher
Justin Boucher
JMJay Mandula
Jay Mandula
JAJulieta Abraham-Miranda
Julieta Abraham-Miranda
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we examined patients’ intratumoral immune infiltrates and observed that elevated levels of immunoregulatory macrophages in pre-infusion tumor biopsies are correlated with poor clinical responses. CAR T cell-produced interferon-gamma (IFN-γ) promotes the expression of inducible nitric oxide synthase (iNOS, NOS2) in immunoregulatory macrophages, impairing CAR T cell function. Mechanistically, iNOS-expressing macrophages upregulated the p53 pathway, mediating apoptosis and cell cycle arrest in CAR T cells, while downregulating the MYC pathway involved in ribosome biogenesis and protein synthesis. Furthermore, CAR T cell metabolism is compromised by depletion of glycolytic intermediates and rewiring of the TCA cycle. Pharmacological inhibition of iNOS enhances the CAR T cell treatment efficacy in B cell tumor-bearing mice. Notably, elevated levels of iNOS+CD14+ monocytes were observed in leukaphereses of patients with non-durable response to CAR T cell therapy. These findings suggest that mitigating iNOS in tumor-associated macrophages (TAMs) by blocking IFN-γ secretion from CAR T cells will improve outcomes for LBCL patients.

Verified
Journal Article
Open access
PDF file
Julio Vázquez-MartínezJulio Vázquez-Martínez
Julio Vázquez-Martínez
MLMiguel Angel Gomez Lim
Miguel Angel Gomez Lim
EMEdgar Morales-Ríos
Edgar Morales-Ríos
JGJorge Alberto Gonzalez-Y-Merchand
Jorge Alberto Gonzalez-Y-Merchand
Vianney Ortiz-NavarreteVianney Ortiz-Navarrete
Vianney Ortiz-Navarrete
Class-I Restricted T Cell-Associated Molecule (CRTAM) is a protein that is expressed after T cell activation. The interaction of CRTAM with its ligand, nectin-like 2 (Necl2), is required for the efficient production of IL-17, IL-22, and IFNγ by murine CD4 T cells, and it plays a role in optimal CD8 T and NK cell cytotoxicity. CRTAM promotes the pro-inflammatory cytokine profile; therefore, it may take part in the immunopathology of autoimmune diseases such as diabetes type 1 or colitis. Thus, antibodies that block the interaction between CRTAM and Necl2 would be useful for controlling the production of these inflammatory cytokines. In this work, using bioinformatics predictions, we identified three short disordered epitopes (sDE1-3) that are located in the Ig-like domains of murine CRTAM and are conserved in mammalian species. We performed a structural analysis by molecular dynamics simulations of sDE1 (QHPALKSSKY, Ig-like V), sDE2 (QRNGEKSVVK, Ig-like C1), and sDE3 (CSTERSKKPPPQI, Ig-like C1). sDE1, which is located within a loop of the contact interface of the heterotypic interaction with Nectl2, undergoes an order–disorder transition. On the contrary, even though sDE2 and sDE3 are flexible and also located within loops, they do not undergo order–disorder transitions. We evaluated the immunogenicity of sDE1 and sDE3 through the expression of these epitopes in chimeric L1 virus-like particles. We confirmed that sDE1 induces polyclonal antibodies that recognize the native folding of CRTAM expressed in activated murine CD4 T cells. In contrast, sDE3 induces polyclonal antibodies that recognize the recombinant protein hCRTAM-Fc, but not the native CRTAM. Thus, in this study, an exposed disordered epitope in the Ig-like V domain of CRTAM was identified as a potential site for therapeutic antibodies.

20 January 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
PPPhaethon Philbrook
Phaethon Philbrook
MDMatthew J. Dean
Matthew J. Dean
MSMaria Dulfary Sanchez-Pino
Maria Dulfary Sanchez-Pino
LZLi Qin Zheng
Li Qin Zheng
JZJovanny Zabaleta
Jovanny Zabaleta
AOAugusto C Ochoa
Augusto C Ochoa
G protein–coupled receptor 84 (GPR84) is a medium-chain free fatty acid receptor predominantly expressed in myeloid cells. Previous studies have identified GPR84 as an enhancer of the pro-inflammatory myeloid cell responses and a regulator of metabolic homeostasis. However, the role of GPR84 in T-cell function and metabolism remains largely unexplored. This study tested the effect of GPR84 modulation on CD8+ T-cell function and metabolism in vitro and examined its effect on antitumor function in adoptive cellular therapy models. Pharmacologic antagonism with GLPG1205 or genetic deletion of GPR84 promoted T-cell differentiation, proliferation, cytokine production, and cytotoxicity, whereas agonism with DL175 reduced these functions. These functional changes were paralleled by changes in metabolic activity. Antagonism and genetic deletion increased glucose uptake, glycolysis, oxidative phosphorylation, and ATP production, which enhanced the overall cell energetic fitness, whereas agonism resulted in a quiescent energetic profile. Furthermore, antagonism or deletion of GPR84 in antigen-specific CD8+ T cells in adoptive cellular therapy models enhanced their antitumor effects in vivo. Thus, GPR84 inhibition improves CD8+ T-cell function and may further enhance adoptive cellular therapies.

2 April 2026
Verified
Other
Open access
PPPhaethon Philbrook
Phaethon Philbrook
MDMatthew J. Dean
Matthew J. Dean
MSMaria Dulfary Sanchez-Pino
Maria Dulfary Sanchez-Pino
LZLi Qin Zheng
Li Qin Zheng
JZJovanny Zabaleta
Jovanny Zabaleta
AOAugusto C Ochoa
Augusto C Ochoa
Granzyme B and Perforin production after exposure to alternative antagonist PBI-4050 and agonist 6-OAU.

2 April 2026
Verified
Other
Open access
PPPhaethon Philbrook
Phaethon Philbrook
MDMatthew J. Dean
Matthew J. Dean
MSMaria Dulfary Sanchez-Pino
Maria Dulfary Sanchez-Pino
LZLi Qin Zheng
Li Qin Zheng
JZJovanny Zabaleta
Jovanny Zabaleta
AOAugusto C Ochoa
Augusto C Ochoa
GLPG1205 increases gene expression of enzymes involved in one-carbon metabolism by single-cell RNA sequencing.

2 April 2026
Verified
Other
Open access
PPPhaethon Philbrook
Phaethon Philbrook
MDMatthew J. Dean
Matthew J. Dean
MSMaria Dulfary Sanchez-Pino
Maria Dulfary Sanchez-Pino
LZLi Qin Zheng
Li Qin Zheng
JZJovanny Zabaleta
Jovanny Zabaleta
AOAugusto C Ochoa
Augusto C Ochoa
GPR84 modulation prevents CD8+ T cell exhaustion after chronic stimulation.